Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid. METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid. Patients were randomly assigned to receive solanezumab at a dose of 400 mg or placebo intravenously every 4 weeks for 76 weeks. The primary outcome was the change from baseline to week 80 in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; scores range from 0 to 90, with higher scores indicating greater cognitive impairment). RESULTS: A total of 2129 patients were enrolled, of whom 1057 were assigned to receive solanezumab and 1072 to receive placebo. The mean change from baseline in the ADAS-cog14 score was 6.65 in the solanezumab group and 7.44 in the placebo group, with no significant between-group difference at week 80 (difference, -0.80; 95% confidence interval, -1.73 to 0.14; P=0.10). As a result of the failure to reach significance with regard to the primary outcome in the prespecified hierarchical analysis, the secondary outcomes were considered to be descriptive and are reported without significance testing. The change from baseline in the MMSE score was -3.17 in the solanezumab group and -3.66 in the placebo group. Adverse cerebral edema or effusion lesions that were observed on magnetic resonance imaging after randomization occurred in 1 patient in the solanezumab group and in 2 in the placebo group. CONCLUSIONS: Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDITION3 ClinicalTrials.gov number, NCT01900665 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the expedition3 trial (NCT01900665), aimed at further validating the drug’s efficacy in patients with mild AD, the drug was declared unsuccessful in 2016, as it failed to meet its primary endpoints.457–459”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [459]
In the citing paper
“In three completed phase 3 clinical trials (EXPEDITION, EXPEDITION2, EXPEDITION3), solanezumab did not significantly reduce the decline in cognition or function (e.g., activities of daily living and community involvement) in patients who had received a clinical diagnosis of mild-to-moderate AD [79].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [79]
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [46]
In the citing paper
“anti-Aβ mAbs that predominantly bind to monomeric Aβ do not mediate substantial removal of plaque and lack clinical efficacy”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [42]
In the citing paper
“A third phase 3 trial in mild AD also failed to demonstrate a significant benefit on the primary endpoint (Honig et al., 2018).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Honig et al., 2018
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Measurement of Functional Activities in Older Adults in the Community
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M., & Filos, S. (1982) · Journal of Gerontology · doi:10.1093/geronj/37.3.323 · Cited by 2,972
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 201–300 of 999
Yao, J., Sun, B., Institoris, A., Zhan, X., Guo, W., Song, Z., Liu, Y., Hiess, F., Boyce, A. K. J., Ni, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108169 · Cited by 65
“However, achieving a sufficient Aβ reduction to prevent induction of neuronal hyperactivity and, consequently, AD progression may be an obstacle, which explains, in part, the failure of some recent Aβ-targeted clinical trials (Chakroborty and Stutzmann, 2014; Honig et al., 2018; Karran et al., 2011).”
BackgroundGroot, C., Smith, R. A., Collij, L. E., Mastenbroek, S. E., Stomrud, E., Binette, A. P., Leuzy, A., Palmqvist, S., Mattsson, N., Strandberg, O. T., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.1612 · Cited by 78
Chen, L., Xu, X., Wu, X., Cao, H., Li, X., Hou, Z., Wang, B., Liu, J., Ji, X., Zhang, P., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.942460 · Cited by 69
“However, no preventative or disease-modifying treatments are available for AD (Honig et al., 2018).”
BackgroundReview on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah, A. E. (2024) · RSC Advances · doi:10.1039/d3ra08333k · Cited by 72
Coley, N., Giulioli, C., Aisen, P. S., Vellas, B., & Andrieu, S. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101777 · Cited by 62
Self-citationThe future of stem cell therapies of Alzheimer’s disease
Wang, Z., Wang, Z.-T., Sun, Y., Tan, L., & Yu, J. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101655 · Cited by 68
Passive immunotherapy for Alzheimer's disease
Guo, X., Li, Y., Zhang, D., & Zhao, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102192 · Cited by 78
Circulating vitamin E levels and Alzheimer's disease: a Mendelian randomization study
Liu, G., Zhao, Y., Jin, S., Hu, Y., Wang, T., Tian, R., Han, Z., Xu, D., & Jiang, Q. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.008 · Cited by 62
Chiu, Y., Lin, C., Lee, M.-C., Hsieh‐Li, H. M., Chen, C., Wu, Y., Chang, K., & Lee‐Chen, G. (2021) · Aging · doi:10.18632/aging.203125 · Cited by 63
“symptomatic, although trials aiming to reduce the production and burden of Aβ aggregation within the brain are underway [8, 9].”
BackgroundXu, Y., Au, N. P. B., & Ma, C. H. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.896852 · Cited by 70
Alkhalifa, A. E., Mokhlf, A. A., Ali, H., Al-Ghraiybah, N. F., & Syropoulou, V. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15090437 · Cited by 77
“First-generation mAbs, such as solanezumab, crenezumab, and gantenerumab, largely failed in clinical trials due to limited efficacy in cognitive endpoints and insufficient plaque clearance [49–51].”
Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?
Checler, F., Afram, E., Pardossi-Piquard, R., & Lauritzen, I. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100489 · Cited by 59
“Solanezumab (monomeric and soluble forms of Aβ Eli Lilly) 170- and 18-fold increase in plasma Aβ40 and Aβ42 respectively no Aβ modulation in brain PET scan (florbetapir) at 400 mg Phase III ongoing in asymptomatic people who have biomarker evidence of brain amyloid deposition Lack of efficacy in mild to moderate AD an…”
BackgroundTau‐PET is superior to phospho‐tau when predicting cognitive decline in symptomatic AD patients
Smith, R., Cullen, N. C., Pichet Binette, A., Leuzy, A., Blennow, K., Zetterberg, H., Klein, G., Borroni, E., Ossenkoppele, R., Janelidze, S., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12875 · Cited by 60
The Future of Anti-Amyloid Trials
Aisen, P. S., Cummings, J., Doody, R., Kramer, L., Salloway, S., Selkoe, D. J., Sims, J., Sperling, R. A., & Vellas, B. (2020) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2020.24 · Cited by 59
Self-citationPanza, F., Lozupone, M., Dibello, V., Greco, A., Daniele, A., Seripa, D., Logroscino, G., & Imbimbo, B. P. (2019) · Immunotherapy · doi:10.2217/imt-2018-0119 · Cited by 60
Kumar, N. N., Pizzo, M. E., Nehra, G., Wilken-Resman, B., Boroumand, S., & Thorne, R. G. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00548 · Cited by 69
Risk factors for subjective cognitive decline: the CABLE study
Chen, W., Hu, H., Ou, Y., Bi, Y., Ma, Y., Tan, L., & Yu, J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01711-1 · Cited by 63
“The failure of several previous clinical trials of therapies in the dementia or mild cognitive impairment (MCI) stages further encouraged researchers to shift their focus to the preclinical stage of AD [2, 3].”
ResultMacfarlane, S., Grimmer, T., Teo, K. G., O'Brien, T. J., Woodward, M., Grunfeld, J. A., Mander, A. G., Brodtmann, A. G., Brew, B. J., Morris, P., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100016 · Cited by 77
Self-citationCai, X., Zhang, K., Xie, X., Zhu, X., Feng, J., Jin, Z., Zhang, H., Tian, M., & Chen, H. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119678 · Cited by 60
Wang, G., Berry, S., Xiong, C., Hassenstab, J., Quintana, M., McDade, E. M., Delmar, P., Vestrucci, M., Sethuraman, G., Bateman, R. J., et al. (2018) · Statistics in Medicine · doi:10.1002/sim.7811 · Cited by 58
Alzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Manap, A. S. A., Almadodi, R., Sultana, S., Sebastian, M. G., Kavani, K. S., Lyenouq, V. E., & Shankar, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1429211 · Cited by 84
Cai, Y., & Wan, J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00370 · Cited by 65
“NDDs are highly complex diseases for which effective drugs and treatments are still lacking (Honig et al., 2018).”
Backgroundvan den Noort, M., Vermeire, K., Bosch, P., Staudte, H., Krajenbrink, T., Jaswetz, L., Struys, E., Yeo, S., Barisch, P., Perriard, B., et al. (2019) · Behavioral Sciences · doi:10.3390/bs9070081 · Cited by 68
Martínková, J., Quevenco, F., Karcher, H., Ferrari, A., Sandset, E. C., Szoeke, C. E. I., Hort, J., Schmidt, R., Chadha, A. S., & Ferretti, M. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24124 · Cited by 68
Ghosh, S., Durgvanshi, S., Agarwal, S., Raghunath, M., & Sinha, J. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200429011823 · Cited by 58
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials
Tian Hui Kwan, A., Arfaie, S., Therriault, J., Rosa-Neto, P., & Gauthier, S. (2020) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000511506 · Cited by 57
Sreenivasmurthy, S. G., Iyaswamy, A., Krishnamoorthi, S., Senapati, S., Malampati, S., Zhu, Z., Su, C.-F., Liu, J., Guan, X.-J., Tong, B. C., et al. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153887 · Cited by 63
Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics
Jeong, H., Shin, H., Hong, S., & Kim, Y. S. (2022) · Experimental Neurobiology · doi:10.5607/en22004 · Cited by 65
“For example, reduced levels of Aβ in the brain were observed in phase II trials of verubecestat, a β-secretase inhibitor drug, and solanezumab, a monoclonal antibody drug of Aβ peptide [12, 13], but they showed no efficacy in phase III trials with worsened cognition in some cases [14, 15].”
BackgroundTau pathology epigenetically remodels the neuron-glial cross-talk in Alzheimer’s disease
Zhou, L., Liu, D., Kang, H., Lu, L., Huang, H., Ai, W.-Q., Zhou, Y., Deng, M., Li, H., Liu, Z., et al. (2023) · Science Advances · doi:10.1126/sciadv.abq7105 · Cited by 61
Lessons Learned from Approval of Aducanumab for Alzheimer's Disease
Heidebrink, J. L., & Paulson, H. L. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-051022-043645 · Cited by 70
Söderberg, L., Johannesson, M., Gkanatsiou, E., Nygren, P., Fritz, N., Zachrisson, O., Rachalski, A., Svensson, A.-S., Button, E. B., Dentoni, G., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-61691-2 · Cited by 71
“All three of these methods found that solanezumab and crenezumab, which have no reported cases of ARIA-E 29–32 , showed no or minimal CAA Aβ fibril binding.”
Passive antiamyloid immunotherapy for Alzheimer's disease
Loureiro, J. C., Pais, M. V., Stella, F., Radanovic, M., Teixeira, A. L., Forlenza, O. V., & de Souza, L. C. (2020) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000587 · Cited by 56
Association of plasma P-tau181 with memory decline in non-demented adults
Therriault, J., Benedet, A. L., Pascoal, T. A., Lussier, F. Z., Tissot, C., Karikari, T. K., Ashton, N. J., Chamoun, M., Bezgin, G., Mathotaarachchi, S., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab136 · Cited by 56
Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer’s Disease
Mantile, F., & Prisco, A. (2020) · Biology · doi:10.3390/biology9120425 · Cited by 56
“Solanezumab, a humanized IgG1 analog of a murine antibody that targets the central domain of Aβ and is selective for soluble forms, failed to improve cognition or functional ability in patients with mild-to-moderate Alzheimer’s disease [89], and in patients with mild dementia due to Alzheimer’s disease [41], and did n…”
BackgroundVenkataraman, L., Fair, S. R., McElroy, C. A., Hester, M. E., & Fu, H. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10068-9 · Cited by 56
Recent advancement in therapeutic strategies for Alzheimer’s disease: Insights from clinical trials
Khan, T., Waseem, R., Shahid, M., Ansari, J., Ahanger, I. A., Hassan, M. I., & Islam, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102113 · Cited by 62
Kamei, N., Okada, N., Ikeda, T., Choi, H., Fujiwara, Y., Okumura, H., & Takeda‐Morishita, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-36210-9 · Cited by 60
Scarpa, M., Hesse, S., & Bradley, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2019.12.003 · Cited by 62
Alzheimer’s disease and gut microbiota: does trimethylamine N-oxide (TMAO) play a role?
Arrona Cardoza, P., Spillane, M. B., & Morales Marroquin, E. (2022) · Nutrition Reviews · doi:10.1093/nutrit/nuab022 · Cited by 53
Promoting Alzheimer’s disease research and therapy with stem cell technology
Cao, Z., Kong, F., Ding, J., Chen, C., He, F., & Deng, W. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03737-w · Cited by 66
“…Aβ and tau pathologies remain the focus of new therapies undergoing clinical trials for AD, which include monoclonal antibodies targeting Aβ[50, 88, 109, 131], the β-secretase (BACE1) inhibitor that inhibits secretase activity to lessen Aβ deposition [35], and drugs that target tau protein…”
BackgroundInsights into the use of biomarkers in clinical trials in Alzheimer's disease
Pascoal, T. A., Aguzzoli, C. S., Lussier, F. Z., Crivelli, L., Suemoto, C. K., Fortea, J., Rosa‐Neto, P., Zimmer, E. R., Ferreira, P. C. L., & Bellaver, B. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105322 · Cited by 67
“16 ,86 – 91 There is currently no consensus regarding cut-off values for determining A β PET positivity.”
Drug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment
Jang, Y.-J., Kang, S.-J., Park, H. S., Lee, D., Kim, J. H., Kim, J.-E., Kim, D., Chung, C., Yoon, J., & Bhang, S. H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03109-3 · Cited by 72
General practitioners’ attitudes towards early diagnosis of dementia: a cross-sectional survey
Giezendanner, S., Monsch, A. U., Kressig, R. W., Mueller, Y. K., Streit, S., Essig, S., Zeller, A., & Bally, K. (2019) · BMC Family Practice · doi:10.1186/s12875-019-0956-1 · Cited by 61
Machine Learning Predictive Models Can Improve Efficacy of Clinical Trials for Alzheimer’s Disease
Ezzati, A., Initiative, A. D. N., & Lipton, R. B. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190822 · Cited by 60
“In fact, recently many drug trials for prodromal AD or mild-AD have been recruiting subjects, with an inclusion criterion based on amyloid PET positivity [27] or CSF amyloid and tau [28].”
Dhage, P. A., Sharbidre, A. A., Dakua, S. P., & Balakrishnan, S. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111634 · Cited by 54
ACU193: An Immunotherapeutic Poised to Test the Amyloid β Oligomer Hypothesis of Alzheimer’s Disease
Krafft, G. A., Jerecìć, J., Siemers, E., & Cline, E. N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.848215 · Cited by 56
Self-citationThe Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes
Kepp, K. P., Sensi, S. L., Johnsen, K. B., Barrio, J. R., Høilund-Carlsen, P. F., Neve, R. L., Alavi, A., Herrup, K., Perry, G., Robakis, N. K., et al. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-230099 · Cited by 53
Zielinski, M., Reyes, F. S. P., Gremer, L., Schemmert, S., Frieg, B., Schäfer, L. U., Willuweit, A., Donner, L., Elvers, M., Nilsson, L. N. G., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01484-4 · Cited by 53
Jiang, L., Li, X., Mortadza, S. A. S., Lovatt, M., & Yang, W. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.07.002 · Cited by 55
Ceyzériat, K., Zilli, T., Millet, P., Frisoni, G. B., Garibotto, V., & Tournier, B. B. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200304085513 · Cited by 51
Amyloid-Beta Solubility in the Treatment of Alzheimer’s Disease
Murphy, M. P. (2018) · New England Journal of Medicine · doi:10.1056/nejme1714638 · Cited by 53
Verger, A., Yakushev, I. Y., Albert, N. L., van Berckel, B. N. M., Brendel, M., Cecchin, D., Fernandez, P. A., Fraioli, F., Guedj, É., Morbelli, S. D., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06177-5 · Cited by 60
Liang, Z., & Li, Q. X. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00010 · Cited by 54
Graphene oxide enhances β-amyloid clearance by inducing autophagy of microglia and neurons
Li, X., Li, K., Chu, F., Huang, J., & Yang, Z. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109126 · Cited by 51
“Some candidate drugs, such as solanezumab monoclonal antibodies that are selectively targets Aβ protein, have been designed to clear Aβ by combining soluble Aβ proteins in blood and brain [10, 11].”
BackgroundApplication of modern neuroimaging technology in the diagnosis and study of Alzheimer's disease
Bai, H., Zeng, H.-M., Han, H., & Zhang, Q. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.286957 · Cited by 56
“Analysis with the ADAS-cog14, which is an AD assessment scale, showed no improvement in cognitive function (Honig et al., 2018).”
Association between Human Blood Metabolome and the Risk of Alzheimer's Disease
Sun, L., Guo, D., Jia, Y., Shi, M., Yang, P., Wang, Y., Liu, F., Chen, G., Zhang, Y., & Zhu, Z. (2022) · Annals of Neurology · doi:10.1002/ana.26464 · Cited by 65
Aranda, M., Márquez, D. X., Gallagher-Thompson, D. E., Pérez, A., Rojas, J. C., Hill, C. V., Reyes, Y., Dilworth‐Anderson, P., & Portacolone, E. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12389 · Cited by 63
Passive Alzheimer’s immunotherapy: A promising or uncertain option?
Høilund‐Carlsen, P. F., Revheim, M.-E. R., Costa, T., Alavi, A. A., Kepp, K. P., Sensi, S. L., Perry, G. L., Robakis, N. K. R. K., Barrio, J. R., & Vissel, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101996 · Cited by 56
Wang, L., Qiao, Y., Zhang, H., Zhang, Y., Hua, J., Jin, S., & Liu, G. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190713 · Cited by 51
“Until now, many clinical trials of therapies for 443 AD have failed, especially the double-blind, placebo444 controlled, phase III trial involving patients with mild 445 dementia due to AD [38, 39].”
BackgroundHe, Z., Han, S., Zhu, H., Hu, X., Li, X., Hou, C., Wu, C., Xie, Q., Li, N., Du, X., et al. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00021 · Cited by 53
NAKAI, T., Yamada, K., & Mizoguchi, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115549 · Cited by 53
African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants
Schindler, S. E., Cruchaga, C., Joseph, A., McCue, L., Farias, F. H. G., Wilkins, C. H., Deming, Y., Henson, R. L., Mikesell, R. J., Piccio, L., et al. (2021) · Neurology Genetics · doi:10.1212/nxg.0000000000000571 · Cited by 49
“A computer algorithm matched each AA participant, if possible, with 1 NHW participant by closest age (within 3 years), years of education (within 2 years), presence of dementia (CDR = 0 or CDR >0), and family history of AD.”
BackgroundInfluentialBayes analysis supports null hypothesis of anti‐amyloid beta therapy in Alzheimer's disease
Richard, E., den Brok, M. G. H. E., & van Gool, W. A. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12379 · Cited by 50
Binder, J., Ursu, O., Bologa, C., Jiang, S., Maphis, N., Dadras, S., Chisholm, D., Weick, J., Myers, O., Kumar, P., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03068-7 · Cited by 49
Barbera, L. L., Nobili, A., Cauzzi, E., Paoletti, I., Federici, M., Saba, L., Giacomet, C., Marino, R., Krashia, P., Melone, M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00580-6 · Cited by 50
Molecular mechanisms and therapeutic potential of icariin in the treatment of Alzheimer's disease
Zheng, L., Wu, S., Jin, H., Wu, J., Wang, X., Cao, Y., Zhou, Z., Jiang, Y., Li, L., Yang, X., et al. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154890 · Cited by 49
Qi, L., Liu, S., Liu, Y.-C., Li, P., & Xu, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115559 · Cited by 54
“Despite significant efforts to reduce Aβ generation, the field has seen little therapeutic success [4,5].”
BackgroundSabbagh, M. N., & Cummings, J. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12235 · Cited by 48
Joseph‐Mathurin, N., Llibre‐Guerra, J. J., Li, Y., McCullough, A. A., Hofmann, C., Wojtowicz, J., Park, E., Wang, G., Preboske, G. M., Wang, Q., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26511 · Cited by 47
Self-citationYuan, C., Guo, X., Zhou, Q., Du, F., Jiang, W., Zhou, X., Liu, P., Chi, T., Ji, X., Gao, J., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.028 · Cited by 53
Time between milestone events in the Alzheimer's disease amyloid cascade
Insel, P. S., Donohue, M. C., Berron, D., Hansson, O., & Mattsson-Carlgren, N. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2020.117676 · Cited by 48
Stefanovski, L., Meier, J. M., Pai, R. K., Triebkorn, P., Lett, T. A. P., Martin, L., Bülau, K., Hofmann‐Apitius, M., Solodkin, A., McIntosh, A. R., et al. (2021) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2021.630172 · Cited by 55
Choroid Plexus Volume, Amyloid Burden, and Cognition in the Alzheimer’s Disease Continuum
Jeong, S. H., Park, C. J., Cha, J., Kim, S.-Y., Lee, S., Kim, Y. J., Sohn, Y. H., Chung, S. J., & Lee, P. H. (2024) · Aging and Disease · doi:10.14336/ad.2024.0118 · Cited by 85
Torshizi, A. D., & Wang, K. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.015 · Cited by 52
Status and future directions of clinical trials in Alzheimer's disease
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.022 · Cited by 47
FLAME: A computerized neuropsychological composite for trials in early dementia
Brooker, H. J., Williams, G. H., Hampshire, A., Corbett, A., Aarsland, D., Cummings, J. L., Molinuevo, J. L., Atri, A., Ismail, Z., Creese, B., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12098 · Cited by 55
“5,6 Although there are more encouraging emerging results for aducanumab, gantenerumab, and BAN2401, 7,8 there are still a very limited number of compounds in phase 2 and phase 3 clinical trials.”
ResultTosun, D., Demir, Z., Veitch, D. P., Weintraub, D., Aisen, P., Jack, C. R., Jagust, W. J., Petersen, R. C., Saykin, A. J., Shaw, L. M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12480 · Cited by 46
Ayton, S., & Bush, A. I. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101212 · Cited by 45
Passive Aβ Immunotherapy: Current Achievements and Future Perspectives
Schilling, S., Rahfeld, J.-U., Lues, I., & Lemere, C. A. (2018) · Molecules · doi:10.3390/molecules23051068 · Cited by 45
“The failures of two monoclonal antibodies in clinical phase III—bapineuzumab and solanezumab [24,25]—contributed to the questioning of the amyloid hypothesis as a basic target for intervention.”
BackgroundImpact of Serum Calcium Levels on Alzheimer’s Disease: A Mendelian Randomization Study
He, Y., Zhang, H., Wang, T., Han, Z., Ni, Q., Wang, K., Wang, L., Zhang, Y., Hu, Y., Jin, S., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191249 · Cited by 50
Recent advancements toward therapeutic vaccines against Alzheimer’s disease
Herline, K., Drummond, E., & Wisniewski, T. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1500905 · Cited by 44
“10) in the change from baseline in ADAS-Cog14 score between the Solanezumab group and placebo group [47].”
BackgroundNotch3ECD immunotherapy improves cerebrovascular responses in CADASIL mice
Ghezali, L., Capone, C., Baron‐Menguy, C., Ratelade, J., Christensen, S., Pedersen, L. Ø., Domenga, V., Pedersen, J. T., & Joutel, A. (2018) · Annals of Neurology · doi:10.1002/ana.25284 · Cited by 48
“However, a recent phase III trial questioned this “peripheral sink” hypothesis, showing that the humanized mAb solanezumab reduced free plasma Aβ concentration by > 90%, but failed to produce clinical efficacy.(24) A recent report suggested that Notch3 can be detected in the plasma(25); however, whether Notch3 exists…”
BackgroundLiu, Y., Du, T., Zhang, W., Lu, W., Peng, Z., Huang, S., Sun, X., Zhu, X., Chen, C., Qian, L., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8340192 · Cited by 53
“Aβ is the hallmark of AD pathology; however, recently, several immunotherapeutic strategies targeting formed Aβ plaque in the brain have proven to be failed in the clinical trials [18, 19].”
Alzheimer’s Disease: Drug Discovery
(2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020 · Cited by 44
Planche, V., & Villain, N. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3126 · Cited by 43
Monoclonal Antibody Therapy in Alzheimer’s Disease
Neațu, M., Covaliu, A., Ioniță, I., Jugurt, A., Davidescu, E. I., & Popescu, B. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010060 · Cited by 48
“After missing the primary endpoint (change from baseline in ADAS-Cog), the secondary measured outcomes were deemed descriptive and with no statistical significance, so the trial was terminated [120,121].”
BackgroundJaved, I., He, J., Käkinen, A., Faridi, A., Yang, W. L., Davis, T. P., Ke, P. C., & Chen, P. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b19506 · Cited by 48
Neuroinflammation in Alzheimer's disease and beneficial action of luteolin
Delgado, A., Cholevas, C., & Theoharides, T. C. (2021) · BioFactors · doi:10.1002/biof.1714 · Cited by 48
Alzheimer’s Disease: Efficacy of Mono- and Combination Therapy. A Systematic Review
Knorz, A. L., & Quante, A. (2021) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887211044746 · Cited by 49
Kaur, K., Narang, R. K., & Singh, S. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230726145447 · Cited by 51
Du, B., Zou, Q., Wang, X., Wang, H., Yang, X., Wang, Q., & Wang, K. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123403 · Cited by 53
Concordance Between Amyloid-PET Quantification and Real-World Visual Reads
Zeltzer, E., Schonhaut, D. R., Mundada, N. S., Blazhenets, G., Mejía, J. A., Soleimani‐Meigooni, D. N., Cho, H., Ranasinghe, K. G., Windon, C., Yadollahikhales, G., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2218 · Cited by 49
Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics
Abreu, C. M., Soares-dos-Reis, R., Melo, P., Relvas, J. B., Guimarães, J., Sá, M. J., Cruz, A., & Pinto, I. M. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00164 · Cited by 43
“Despite the supporting evidence of the innate immunity pathways in AD pathogenesis, attempts to modulate the inflammatory response in patients with AD have mostly failed at improving cognition and halting disease progression (Bronzuoli et al., 2016; Dansokho and Heneka, 2017; Honig et al., 2018).”
BackgroundPlasma lipocalin‐2 levels in the preclinical stage of Alzheimer's disease
Eruysal, E., Ravdin, L., Kamel, H., Iadecola, C., & Ishii, M. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.07.004 · Cited by 46
Sarazin, M., Lagarde, J., Haddad, I., de Souza, L. C., Bellier, B., Potier, M., Bottlaender, M., & Dorothée, G. (2024) · Nature Aging · doi:10.1038/s43587-024-00630-2 · Cited by 46
Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
Nimmo, J., Kelly, L., Verma, A. K., Carare, R. O., Nicoll, J. A. R., & Dodart, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.733857 · Cited by 45
Integrated Alzheimer's Disease Rating Scale: Clinically meaningful change estimates
Wessels, A. M., Rentz, D. M., Case, M., Lauzon, S., & Sims, J. R. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12312 · Cited by 40
Self-citationTesting the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease
Levin, J., Vöglein, J., Quiroz, Y. T., Bateman, R. J., Ghisays, V., Lopera, F., McDade, E., Reiman, E., Tariot, P. N., & Morris, J. C. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12624 · Cited by 40
Schwarz, A. J., Sundell, K. L., Charil, A., Case, M. G., Jaeger, R. K., Scott, D., Bracoud, L., Oh, J., Suhy, J., Pontecorvo, M. J., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.05.007 · Cited by 40
Self-citationSharma, H., & Chandra, P. (2023) · International Journal of Pharmaceutical Investigation · doi:10.5530/ijpi.14.1.15 · Cited by 50
Metadata
- Authors
- Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., Case, M., Dean, R. A., Hake, A., Sundell, K., Poole Hoffmann, V., Carlson, C., Khanna, R., Mintun, M., DeMattos, R., Selzler, K. J., & Siemers, E.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From the Department of Neurology and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); Gérontopôle, Centre Hospitalier Universitaire Toulouse, Unité Mixte de Recherche INSERM Unité 1027 Université Toulouse III–Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC — both in Australia (M.W.); Fundació ACE, Alzheimer Research...
- Western University (CA)
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-01-25
- Volume
- 378
- Issue
- 4
- Pages
- 321-330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2787612390
- Cited by
- 1,049
- References
- 27
- Citations by year
- 2026: 48 · 2025: 93 · 2024: 121 · 2023: 123 · 2022: 136 · 2021: 129 · 2020: 169 · 2019: 136 · 2018: 91
- FWCI
- 90.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- IUScholarWorks (Indiana University) (submittedVersion)
- Publisher
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, mild dementia, amyloid-beta, humanized monoclonal antibody, amyloid-beta clearance, cognitive decline, florbetapir PET, cerebral edema, treatment efficacy, amyloid plaques, neurofibrillary tangles
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Humans, Immunotherapy, Infusions, Intravenous, Male, Middle Aged, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Treatment Failure, Positron-Emission Tomography, Plaque, Amyloid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.